This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1.DM Eisenberg , RC Kessler , C Foster , FE Norlock , DR Calkins & TL Delbanco (1993) Unconventional medicine in the United States. Prevalence, costs and pattern of use. N Engl J Med 328, 246–252.
2.E Ernst & BR Cassileth (1999) How useful are unconventional cancer treatments? Eur J Cancer 35, 1608–1613.
4.U Werneke , T Turner & S Priebe (2006) Complementary alternative medicine in psychiatry: a review of effectiveness and safety. Br J Psych 188, 109–121.
6.J Unutzer , R Klap , R Sturm , AS Young , T Marmon , J Shatkin & KB Wells (2000) Mental disorders and the use of alternative medicine: results from a national survey. Am J Psychiatry 157, 1851–1857.
12.EN Drake (2006) Cancer chemoprevention: selenium as a prooxidant, not an antioxidant. Med Hypotheses 67, 318–322.
15.EH Turner & AD Blackwell (2005) 5-Hydroxytryptophan plus SSRIs for interferon-induced depression: synergistic mechanisms for normalizing synaptic serotonin. Med Hypothesis 65, 138–144.
16.K Shaw , J Turner & C Del Mar (2002) Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Aust N Z J Psychiatry 36, 488–491.
18.M Morris , M Fava & PF Jaques (2003) Depression and folate status in the US population. Psychothep Psychosom 72, 80–87.
19.G Schreiber & S Avissar (2005) Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action. Expert Rev Neurother 7, 75–84.
20.CG Hahn , Umapathy , HY Wang , R Koneru , DF Levinson & E Friedman (2005) Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J Psychiatr Res 39, 355–363.
23.MJ Taylor , S Carney , J Geddes & G Goodwin (2003) Folate for depressive disorders. Cochrane Database of Systematic Reviews, issue 2, art no. CD003390. Chichester, West Sussex: John Wiley & Sons Ltd.
24.B Hallahan & MR Garland (2005) Essential fatty acids and mental health. Br J Psychiatry 186, 275–277.
25.MP Freeman , JR Hibbeln , KL Wisner (2006) Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 67, 1954–1967.
27.SM Dursun , JR Blackburn & SP Kutcher (2001) An exploratory approach to the serotonergic hypothesis of depression: bridging the synaptic gap. Med Hypothesis 56, 235–243.
28.L Cheng , M Lumb , L Polgar & AW Mudge (2005) How can the mood stabilizer VPA limit both mania and depression? Mol Cell Neurosci 29, 155–161.
30.J Levine (1997) Controlled trials of inositol in psychiatry. Eur Neuropsychopharmacol 7, 147–155.
31.AA Nierenberg , MJ Ostacher , JR Calabrese (2006) Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 163, 210–216.
32.A Eden Evins , C Demopulos , I Yovel , M Culhane , J Ogutha , LD Grandin , AA Nierenberg & GS Sachs (2006) Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord 8, 168–174.
34.A Castano , A Ayala , JA Rodriguez-Gomez , AJ Herrera , J Cano & A Machado (1997) Low selenium diet increases the dopamine turnover in prefrontal cortex of the rat. Neurochem Int 30, 549–555.
35.WC Hawkes & L Hornbostel (1996) Effects of dietary selenium on mood in healthy men living in a metabolic research unit. Biol Psychiatry 39, 121–128.
38.KM Hayden , KA Welsh-Bohmer , HJ Wengreen , P Zandi , C Lyketsos & J Breitner (2007) Risk of mortality with vitamin E supplements: the Cache County study. Am J Med 120, 180–184.
41.PC Dagnelie , AG Schuurman , RA Goldbohm & PA Van den Brandt (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93, 1139–1150.
44.U Werneke , J Earl , C Seydel , O Horn , P Crichton & D Fannon (2004) Potential health risks of complementary alternative medicines in cancer patients. Br J Cancer 90, 408–413.
47.HE Bays (2006) Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 99, 35C–43C.
49.TJ Simat , KK Kleeberg , B Muller & A Sierts (1999) Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan. Adv Exp Med Biol 467, 469–480.
55.GM D'Andrea (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin 55, 319–321.
57.AL Stoll , WE Severus , MP Freeman , S Rueter , HA Zboyan , E Diamond , KK Cress & LB Marangell (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56, 407–412.
58.WS Harris (2007) Expert opinion: omega-3 fatty acids and bleeding – cause for concern? Am J Cardiol 99, 44C–46C.
59.EM McClaskey & E Michalets (2007) Subdural hematoma after a fall in an elderly patient taking high-dose omega-3 fatty acids with warfarin and aspirin: case report and review of the literature. Pharmacotherapy 27, 152–160.
63.SM Bryant & J Kolodchak (2004) Serotonin syndrome resulting from a herbal detox cocktail. Am J Emerg Med 22, 625–626.
64.HA Friedel , KL Goa & P Benfield (1989) S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. Drugs 38, 389–416.
73.G Bjelakovic , D Nikolova , RG Simonetti & C Gluud (2004) Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 364, 1219–1228.
74.G Lodi , A Sardella , C Bez , F Demarosi & A Carrassi (2006) Interventions for treating oral leukoplakia. Cochrane Database of Systematic Reviews, issue 4, art. no. CD001829. Chichester, West Sussex: John Wiley & Sons Ltd.
84.MC Nollevaux , Y Guiot , Y Horsmans , I Leclercq , J Rahier , AP Geubel & C Sempoux (2006) Hypervitaminosis A-induced liver fibrosis: stellate cell activation and daily dose consumption. Liver Int 26, 182–186.
85.WC Maddrey (2005) Drug-induced hepatotoxicity. J Clin Gastroenterol 39, Suppl. 2, S83–S89.
87.DI Friedman (2005) Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 6, 29–37.
88.FW Fraunfelder & FT Fraunfelder (2004) Evidence for a probable causal relationship between tretinoin, acitretin, and etretinate and intracranial hypertension. J Neuroophthalmol 24, 214–216.
90.M Fakih , S Cao , FA Durrani & YM Rustum (2005) Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer 5, 132–135.
91.RG Azrak , S Cao , L Pendyala , F Durrani , M Fakih , G Combs , J Prey , P Smith & Y Rustum (2007) Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochem Pharmacol 73, 1280–1287.
93.J Kohrle (2005) Selenium and the control of thyroid hormone metabolism. Thyroid 15, 841–853.
95.A Pace , A Savarese , M Picardo (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21, 927–931.
101.H Koller , C Luley , B Klein , H Baum & HK Biesalski (1989) Contaminating substances in 22 over-the-counter fish oil and cod liver oil preparations: cholesterol, heavy metals and vitamin A. Z Ernahrungswiss 28, 76–83.